Maybe you are right, the OTC is where it is at, THERF is doing great. Can you confidently say it is because they are on the otc? Where would they be if they were on the nasdaq? Do you think all biotechs should be on the otc? My point is that this stock appreciation shown in THERF has not happened with CYDY despite the development in pro 140 - to assume something is wrong with pro 140 is unfounded so therefore being on the otc is a logical explanation for the poor stock performance. I absolutely could be wrong and there might have been some poor decisions by management but i really can't see what i would do different in this situation. Some here have made the claim that mgmt is at fault but they don't seem to stick there neck out with what they would do. As far as i can tell mgmt is moving the development of pro 140 forward as fast as possible with as little dilution as possible. Is it a mistake to waste the effort to get on the nasdaq? Is it worth the risk of not getting a broader set of investors on a large market?
News 
Market Data 
Discover 
AI
